The Europe infectious disease therapeutics market was valued at US$ 35.45 billion in 2022 and is expected to reach US$ 49.10 billion by 2030; it is estimated to register a CAGR of 4.2% from 2022 to 2030.
In order to create solutions for the most important health issues that Europe and the rest of the world are currently encountering, the European Union is investing in research, technology, and innovation. The European Commission has led the way in promoting research, particularly that related to immunity to and management of infectious diseases. Between 2007 and 2019, more than US$ 4.3 billion (4 billion) was allocated to the study of infectious diseases. Further, Horizon Europe, the upcoming (2021-2027) EU funding initiative for research and innovation (R&I), will carry on supporting R&I for infectious diseases, notably those associated with poverty, those that are neglected, and those that are (re-)emerging.
Horizon Europe is a program dedicated to supporting research and innovation. To bridge barriers across regions and establish tangible collaborations, the program places a strong emphasis on ensuring cooperation between universities, scientific communities, industry, especially small and medium-sized firms, and individuals. The Health Work Programme outlines funding options under Horizon Europe for research related to infectious diseases and pandemic preparedness and response. Thus, rising focus on R&D and funding in infectious disease therapeutics drive the infectious disease therapeutics market growth.
According to The Robert Koch Institute, in Germany, ~400,000 to 600,000 patients suffer a hospital-acquired infection each year, among which 10,000-15,000 die. Typical problems for healthcare providers are surgical site infections, urinary tract infections, and pneumonia. The demand for anti-infective agents in Germany is growing significantly, attributed to the rising geriatric population, the increasing prevalence of chronic viral diseases, and the growing demand to produce new molecules for viral therapeutic areas to fulfill unmet conditions.
Germany is one of the leading nations for anti-viral agent manufacturing and growth potential in Europe due to the high quality of its finished products. For instance, Atriva Therapeutics GmbH, a biopharmaceutical company, developed ATR-002 to treat patients with COVID-19 in a Phase II Study to block viral propagation of SARS-CoV-2. Therefore, due to the abovementioned factors, the market is expected to grow significantly in the country.
Increasing Focus on Funding and R&D in Infectious Disease Therapeutics Drives Europe Infectious Disease Therapeutics Market
Research and development (R&D) is a critical part of the business of biopharmaceuticals and pharmaceutical companies. R&D enables them to launch new products for several therapeutic applications with significant medical and commercial potential. Also, leading market players are investing in R&D to develop enhanced technologies and gain more revenue share.In order to create solutions for the most important health issues that Europe and the rest of the world are currently encountering, the European Union is investing in research, technology, and innovation. The European Commission has led the way in promoting research, particularly that related to immunity to and management of infectious diseases. Between 2007 and 2019, more than US$ 4.3 billion (4 billion) was allocated to the study of infectious diseases. Further, Horizon Europe, the upcoming (2021-2027) EU funding initiative for research and innovation (R&I), will carry on supporting R&I for infectious diseases, notably those associated with poverty, those that are neglected, and those that are (re-)emerging.
Horizon Europe is a program dedicated to supporting research and innovation. To bridge barriers across regions and establish tangible collaborations, the program places a strong emphasis on ensuring cooperation between universities, scientific communities, industry, especially small and medium-sized firms, and individuals. The Health Work Programme outlines funding options under Horizon Europe for research related to infectious diseases and pandemic preparedness and response. Thus, rising focus on R&D and funding in infectious disease therapeutics drive the infectious disease therapeutics market growth.
Europe Infectious Disease Therapeutics Market Overview
The Europe infectious disease therapeutics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Europe occupies a significant position in the global infectious disease therapeutics market and is estimated to register a notable CAGR during 2022-2030. The region has an increased incidence of chronic viral diseases and a high demand for developing new anti-viral drugs. With US$ 15.79 billion funded from 2007 to 2019 through the 7th Framework Program and Horizon 2020 and the US$ 1.1 billion pledged for COVID-19 research, Europe plays a crucial role in funding and coordinating research on infectious diseases.According to The Robert Koch Institute, in Germany, ~400,000 to 600,000 patients suffer a hospital-acquired infection each year, among which 10,000-15,000 die. Typical problems for healthcare providers are surgical site infections, urinary tract infections, and pneumonia. The demand for anti-infective agents in Germany is growing significantly, attributed to the rising geriatric population, the increasing prevalence of chronic viral diseases, and the growing demand to produce new molecules for viral therapeutic areas to fulfill unmet conditions.
Germany is one of the leading nations for anti-viral agent manufacturing and growth potential in Europe due to the high quality of its finished products. For instance, Atriva Therapeutics GmbH, a biopharmaceutical company, developed ATR-002 to treat patients with COVID-19 in a Phase II Study to block viral propagation of SARS-CoV-2. Therefore, due to the abovementioned factors, the market is expected to grow significantly in the country.
Europe Infectious Disease Therapeutics Market Segmentation
The Europe infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.- Based on drug class, the Europe infectious disease therapeutics market is segmented into anti-viral, anti bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.
- In terms of indication, the Europe infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.
- Based on route of administration, the Europe infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.
- In terms of distribution channel, the Europe infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.
- By country, the Europe infectious disease therapeutics market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe infectious disease therapeutics market share in 2022.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Europe Infectious Disease Therapeutics Market - Key Market Dynamics
5. Infectious Disease Therapeutics Market - Europe Analysis
6. Europe Infectious Disease Therapeutics Market Analysis - by Drug Class
7. Europe Infectious Disease Therapeutics Market Analysis - by Indication
8. Europe Infectious Disease Therapeutics Market Analysis - by Route of Administration
9. Europe Infectious Disease Therapeutics Market Analysis - by Distribution Channel
10. Europe Infectious Disease Therapeutics Market - Country Analysis
11. Infectious Disease Therapeutics Market-Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned
- AbbVie Inc
- Astellas Pharma Inc
- Bayer AG
- BioCryst Pharmaceuticals Inc
- F. Hoffmann-La Roche Ltd
- Gilead Sciences Inc
- GSK Plc
- Merck & Co Inc
- Pfizer Inc
- Shionogi & Co Ltd
